Skip Navigation


JAC Advance Access originally published online on June 23, 2006
Journal of Antimicrobial Chemotherapy 2006 58(2):479-480; doi:10.1093/jac/dkl255
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
58/2/479    most recent
dkl255v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Paul, M.
Right arrow Articles by Leibovici, L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Paul, M.
Right arrow Articles by Leibovici, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Correspondence

Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials: authors’ response

Mical Paul1,2,*, Abigail Fraser1,{dagger} and Leonard Leibovici1,2

1 Department of Medicine E, Rabin Medical Center Beilinson Campus, 49100 Petah-Tiqva, Israel 2 Sackler Faculty of Medicine, Tel-Aviv University Ramat-Aviv, Israel

*Correspondence address. Department of Medicine E, Rabin Medical Center, Beilinson Campus, 49100 Petah-Tiqva, Israel. Tel: +972-3-9376501; Fax: +972-3-9376512; E-mail: pil1pel@zahav.net.il

Keywords: neutropenic sepsis , antimicrobials , ß-lactams

The first 10% of the full text of this article appears below.

Sir,

Drs Rolston and Bodey1 have raised several points regarding our study, which we would like to address.

We compared broad-spectrum ß-lactams currently recommended as first-line empirical monotherapy for febrile neutropenia in the latest Infectious Diseases Society of America (IDSA) guidelines, which include ceftazidime, cefepime, imipenem and meropenem.2 Indeed, our terminology (i.e. monotherapy) was inaccurate since we included studies that assessed combination therapy when . . . [Full Text of this Article]

Transparency declarations


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
J. Sonck, G. Laureys, and D. Verbeelen
The neurotoxicity and safety of treatment with cefepime in patients with renal failure
Nephrol. Dial. Transplant., March 1, 2008; 23(3): 966 - 970.
[Abstract] [Full Text] [PDF]